度普利尤单抗治疗日本难治性慢性鼻窦炎伴鼻息肉的疗效
该研究基于SINUS-52研究,评估度普利尤单抗在日本慢性鼻窦炎伴鼻息肉(CRSwNP)患者中的疗效。49例日本患者随机接受度普利尤单抗300mg每2周(A组)、先每2周24周后每4周(B组)或安慰剂(C组),背景为糠酸莫米松鼻喷雾剂。第24周时,A组和B组在鼻息肉评分、鼻塞评分和Lund-Mackay CT评分上均显著优于安慰剂。
要点
- 度普利尤单抗在日本CRSwNP患者中快速显著改善鼻息肉大小、鼻塞和鼻窦浑浊。
- 第24周鼻息肉评分较安慰剂改善:A组-3.1(P<.0001),B组-2.1(P=.0011)。
- 安全性与总体研究人群一致,最常见治疗中出现的不良事件为鼻咽炎。
核心结论
- 度普利尤单抗为日本CRSwNP患者提供快速、显著且有临床意义的改善,且耐受性良好。
研究设计与样本
- SINUS-52研究(NCT02898454)的日本中心亚组分析,纳入49例日本CRSwNP患者,45例完成研究。
- 患者背景治疗为糠酸莫米松鼻喷雾剂,随机分为A组(度普利尤单抗300mg每2周,52周)、B组(300mg每2周24周后每4周28周)或C组(安慰剂)。
- 共同主要终点为第24周鼻息肉评分(NPS)、鼻塞(NC)评分和鼻窦Lund-Mackay CT(LMK-CT)评分。
主要发现
- 第24周NPS最小二乘均值改善vs安慰剂:A组-3.1(P<.0001),B组-2.1(P=.0011)。
- 第24周NC评分改善vs安慰剂:A组-1.2(P<.0001),B组-0.9(P<.0001)。
- 第24周LMK-CT评分改善vs安慰剂:A组-5.1(P=.0005),B组-2.8(P=.0425)。
- 度普利尤单抗和安慰剂组最常见治疗中出现的不良事件为鼻咽炎。
关键数值与推荐
- 第24周NPS较安慰剂改善:A组-3.1(P<.0001),B组-2.1(P=.0011)。
- 第24周NC评分较安慰剂改善:A组-1.2(P<.0001),B组-0.9(P<.0001)。
- 第24周LMK-CT评分较安慰剂改善:A组-5.1(P=.0005),B组-2.8(P=.0425)。
临床怎么用
- 对于日本难治性CRSwNP患者,度普利尤单抗300mg每2周可显著改善鼻息肉、鼻塞和鼻窦CT评分。
- 治疗期间需关注鼻咽炎等常见不良事件,安全性总体与整体研究人群一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES/HYPOTHESIS: Dupilumab, which blocks the shared receptor component for interleukin-4 and interleukin-13, reduced polyp size, sinus opacification, and symptom severity, and was well tolerated in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in the SINUS-52 study (NCT02898454). We assessed dupilumab in patients enrolled at Japanese centers. METHODS: Patients on a background of mometasone furoate nasal spray, received dupilumab 300 mg every 2 weeks (q2w) for 52 weeks (Arm A); dupilumab 300 mg q2w for 24 weeks, followed by every 4 weeks (q4w) for 28 weeks (Arm B); or placebo (Arm C). Co-primary endpoints were week 24 nasal polyp score (NPS), nasal congestion (NC) score, and sinus Lund-Mackay CT (LMK-CT) scores. Symptoms, sense of smell, health-related quality of life, and safety were assessed during the 52-week treatment period. RESULTS: Of 49 patients enrolled in Japan, 45 completed the study. Week 24 least squares (LS) mean improvement versus placebo were as follows: NPS (Arm A: -3.1, P < .0001; Arm B: -2.1, P = .0011); NC score (Arm A: -1.2, P < .0001; Arm B: -0.9, P < .0001); and LMK-CT (Arm A: -5.1, P = .0005; Arm B: -2.8, P = .0425). The most common treatment-emergent adverse event in dupilumab and placebo-treated patients was nasopharyngitis. CONCLUSION: Dupilumab provided rapid, significant, and clinically meaningful improvements for patients with CRSwNP in Japan. Dupilumab was well tolerated, and safety and efficacy were consistent with the overall study population. LEVEL OF EVIDENCE: 2 Laryngoscope, 131:E1770-E1777, 2021.
引用
- Fujieda S, Matsune S, Takeno S, et al. The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan. Laryngoscope. 2020. PMID: 33226139. doi:10.1002/lary.29230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。